MX2015011505A - Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos. - Google Patents
Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos.Info
- Publication number
- MX2015011505A MX2015011505A MX2015011505A MX2015011505A MX2015011505A MX 2015011505 A MX2015011505 A MX 2015011505A MX 2015011505 A MX2015011505 A MX 2015011505A MX 2015011505 A MX2015011505 A MX 2015011505A MX 2015011505 A MX2015011505 A MX 2015011505A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- hepatocytes
- stem cell
- cell differentiation
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La invención se relaciona con compuestos de fórmula I y sales farmacéuticamente aceptables y ésteres del mismo, donde R1 - R11 son como se definen en la descripción indicaciones. Además, la presente invención se relaciona con los métodos de fabricación y utiliza compuestos de fórmula I así como composiciones farmacéuticas que contengan dichos compuestos. Los compuestos de formula I son útiles para diferenciar células madre de células más adultas como hepatocitos para usarse en plataformas de selección de fármacos y en aplicaciones de modelado de la enfermedad.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361792019P | 2013-03-15 | 2013-03-15 | |
US201361811155P | 2013-05-22 | 2013-05-22 | |
PCT/EP2014/054763 WO2014140058A1 (en) | 2013-03-15 | 2014-03-12 | Compounds for improved stem cell differentiation into hepatocytes |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015011505A true MX2015011505A (es) | 2016-01-22 |
MX346497B MX346497B (es) | 2017-03-22 |
Family
ID=50272618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011505A MX346497B (es) | 2013-03-15 | 2014-03-12 | Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US9334480B2 (es) |
EP (1) | EP2970178B1 (es) |
JP (1) | JP6129360B2 (es) |
KR (1) | KR101767802B1 (es) |
CN (1) | CN105051023B (es) |
BR (1) | BR112015023185A2 (es) |
CA (1) | CA2900690A1 (es) |
HK (1) | HK1217199A1 (es) |
MX (1) | MX346497B (es) |
RU (1) | RU2662954C2 (es) |
WO (1) | WO2014140058A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3720441A1 (en) * | 2017-12-04 | 2020-10-14 | H. Hoffnabb-La Roche Ag | Pyrrolo[2,3-b]pyrazine compounds as cccdna inhibitors for the treatment of hepatitis b virus (hbv) infection |
JP2023516484A (ja) | 2020-03-11 | 2023-04-19 | ビット バイオ リミテッド | 肝細胞作製方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
CA2536934A1 (en) * | 2003-08-27 | 2005-03-17 | Renomedix Institute Inc. | Method for differentiating mesenchymal stem cell into hepatocyte and artificial human hepatocyte |
EA016633B1 (ru) * | 2006-05-23 | 2012-06-29 | Общество С Ограниченной Ответственностью "Инновационная Фармацевтика" | Замещенные индолы, способ их получения и применения |
ES2660756T3 (es) * | 2011-04-15 | 2018-03-26 | National University Corporation Tottori University | Síntesis y análisis de nuevos compuestos capaces de inducir la diferenciación de célula madre mesenquimal humana en hepatocito |
-
2014
- 2014-03-12 BR BR112015023185A patent/BR112015023185A2/pt not_active IP Right Cessation
- 2014-03-12 MX MX2015011505A patent/MX346497B/es active IP Right Grant
- 2014-03-12 CN CN201480012330.0A patent/CN105051023B/zh not_active Expired - Fee Related
- 2014-03-12 RU RU2015140469A patent/RU2662954C2/ru not_active IP Right Cessation
- 2014-03-12 CA CA2900690A patent/CA2900690A1/en not_active Abandoned
- 2014-03-12 US US14/205,893 patent/US9334480B2/en active Active
- 2014-03-12 WO PCT/EP2014/054763 patent/WO2014140058A1/en active Application Filing
- 2014-03-12 KR KR1020157025369A patent/KR101767802B1/ko active IP Right Grant
- 2014-03-12 JP JP2015562101A patent/JP6129360B2/ja not_active Expired - Fee Related
- 2014-03-12 EP EP14709646.5A patent/EP2970178B1/en not_active Not-in-force
-
2015
- 2015-02-03 US US14/612,893 patent/US9181218B2/en not_active Expired - Fee Related
-
2016
- 2016-05-09 HK HK16105247.2A patent/HK1217199A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP6129360B2 (ja) | 2017-05-17 |
US20150197726A1 (en) | 2015-07-16 |
HK1217199A1 (zh) | 2016-12-30 |
US9181218B2 (en) | 2015-11-10 |
RU2662954C2 (ru) | 2018-07-31 |
EP2970178A1 (en) | 2016-01-20 |
CA2900690A1 (en) | 2014-09-18 |
US20150158840A1 (en) | 2015-06-11 |
EP2970178B1 (en) | 2017-06-14 |
BR112015023185A2 (pt) | 2017-07-18 |
KR20150119342A (ko) | 2015-10-23 |
JP2016511276A (ja) | 2016-04-14 |
WO2014140058A1 (en) | 2014-09-18 |
RU2015140469A (ru) | 2017-04-21 |
CN105051023B (zh) | 2017-08-22 |
US9334480B2 (en) | 2016-05-10 |
KR101767802B1 (ko) | 2017-08-11 |
MX346497B (es) | 2017-03-22 |
CN105051023A (zh) | 2015-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
EA201400833A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
NZ704662A (en) | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid | |
EA201491671A1 (ru) | Гетероциклильные соединения | |
IN2014DN09348A (es) | ||
BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
NZ729443A (en) | Heterocyclic modulators of lipid synthesis | |
MD20140073A2 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
EP2940014A4 (en) | 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK-KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREWITH | |
WO2014045162A8 (en) | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS | |
IN2015DN01119A (es) | ||
MX2016000906A (es) | Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
WO2013006734A8 (en) | Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity | |
TR201009167A2 (tr) | Sefalosporin içeren farmasötik granüller. | |
PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
MD20160111A2 (ro) | Derivaţi diheterociclici legaţi de cicloalchil | |
MX2015011505A (es) | Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos. | |
MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
WO2015023631A3 (en) | Fatty acid analogs and their use | |
MX351994B (es) | Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico. | |
IN2012CH03125A (es) | ||
WO2015036898A3 (en) | Novel salts of crizotinib and their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |